Hybrid Silica-Coated PLGA Nanoparticles for Enhanced Enzyme-Based Therapeutics

Kyle T. Gustafson, Negin Mokhtari, Elise C. Manalo, Jose Montoya Mira, Austin Gower, Ya San Yeh, Mukanth Vaidyanathan, Sadik C. Esener, Jared M. Fischer

Research output: Contribution to journalArticlepeer-review


Some cancer cells rely heavily on non-essential biomolecules for survival, growth, and proliferation. Enzyme based therapeutics can eliminate these biomolecules, thus specifically targeting neoplastic cells; however, enzyme therapeutics are susceptible to immune clearance, exhibit short half-lives, and require frequent administration. Encapsulation of therapeutic cargo within biocompatible and biodegradable poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) is a strategy for controlled release. Unfortunately, PLGA NPs exhibit burst release of cargo shortly after delivery or upon introduction to aqueous environments where they decompose via hydrolysis. Here, we show the generation of hybrid silica-coated PLGA (SiLGA) NPs as viable drug delivery vehicles exhibiting sub-200 nm diameters, a metastable Zeta potential, and high loading efficiency and content. Compared to uncoated PLGA NPs, SiLGA NPs offer greater retention of enzymatic activity and slow the burst release of cargo. Thus, SiLGA encapsulation of therapeutic enzymes, such as asparaginase, could reduce frequency of administration, increase half-life, and improve efficacy for patients with a range of diseases.

Original languageEnglish (US)
Article number143
Issue number1
StatePublished - Jan 2023


  • amino acid depletion
  • biocompatible
  • cancer
  • double emulsion
  • drug delivery
  • enzymes
  • nanoparticles
  • poly(lactic-co-glycolic acid)
  • silica

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Hybrid Silica-Coated PLGA Nanoparticles for Enhanced Enzyme-Based Therapeutics'. Together they form a unique fingerprint.

Cite this